Nancy Chan, Md

This study is testing whether adding an immunotherapy drug (pembrolizumab) to a standard hormone-blocking drug (fulvestrant) can better control advanced breast cancer that has spread. It enrolled 47 adults whose cancer is fueled by hormones but not by the HER2 protein, and who ha…